



- (51) **International Patent Classification:**
C12N 5/0775 (2010.01) A61K 8/98 (2006.01)
A61Q 19/08 (2006.01)
- (21) **International Application Number:**
PCT/US2014/065627
- (22) **International Filing Date:**
14 November 2014 (14.11.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/904,021 14 November 2013 (14.11.2013) US
- (71) **Applicant:** DERMARCHE LABS, LLC [US/US]; 4747 N. Scottsdale Road, Suite 1009, Scottsdale, AZ 85251 (US).
- (72) **Inventors:** SHACKNAI, Jonah; 4747 North Scottsdale Road, Suite 1009, Scottsdale, AZ 85251 (US). WORTZMAN, Mitchell, S.; 8275 E Captain Dreyfus Ave., Scottsdale, AZ 85260-9411 (US). McDANIEL, David, H.; 3033 Little Haven Road, Virginia Beach, VA 23452 (US).
- (74) **Agent:** RUGGIERO, Charles, N.J.; Ohlandt, Greeley, Ruggiero & Perle, L.L.P., One Landmark Square, 10th Floor, Stamford, CT 06901 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))


Published:

— with international search report (Art. 21(3))

(54) **Title:** FIBROBLAST MIXTURES AND METHODS OF MAKING AND USING THE SAME

FIG. 1

Expression Profile: Graph #1
African American vs CoCulture



(57) **Abstract:** The present disclosure provides a non-autologous product that is a mixture of two or more cells or tissue cultures of fibroblast, or extracts from cultures, or media cultures, isolated from separate individuals, either homogeneous or heterogeneous. The cells or factors are blended together in a product that imparts desired characteristics to the skin of a recipient who is not a source of the mixture. The present disclosure also relates to methods of making and using and/or culturing the fibroblasts including to optimize the potency of the mixture to impart one or more the desired characteristics to the skin of a recipient.

WO 2015/073778 A1

FIBROBLAST MIXTURES AND METHODS OF MAKING AND USING THE SAME

BACKGROUND OF THE DISCLOSURE

1. Field of the Disclosure

[0001] The present disclosure relates to a mixture of two or more tissue cultures of fibroblast, or extracts from cultures, or media cultures isolated from separate individuals, either homogeneous or heterogeneous. The present disclosure further relates to the use of such fibroblast cultures, coculture of cells, extracts from cells, diffusible elements that form the cell culture or culture media, either alone or with environmental conditions, to grow the cells and induce them to produce their array of factors or elements produced by or extracted from the cells. The present disclosure still further relates that these cells or factors are blended together in a product that imparts desired characteristics to the skin of a recipient who is not a source of the mixture and any individual fibroblasts, namely non-autologous. The present disclosure also relates to methods of making and using and/or culturing the fibroblasts and the mixtures thereof including methods for optimizing the potency or potential of the cells or factors in a mixture to impart the desired characteristics to the recipient's skin.

2. Description of the Related Art

[0002] One of the primary functions of a fibroblast is to maintain the structural integrity of connective tissues by continuously secreting precursors of the extracellular matrix. A fibroblast secretes precursors of all components of the extracellular matrix, primarily the ground substance and a variety of fibers or structural proteins. They also secrete small molecular weight

diffusible factors that influence and coordinate the function and product of neighboring cells to enhance tissue response. The composition of the extracellular matrix significantly determines the physical properties of connective tissues.

[0003] Known in the art are methods of treatment using autologous fibroblasts (i.e. fibroblast obtained from a donor who will also be the recipient of cultured fibroblasts). Among the known uses of such fibroblasts are a method of promoting healing of wounds, such as an epithelial wound or fistula, by administering cultured fibroblasts; a method of corrective surgery by the augmentation of tissue sub-adjacent to a vocal cord defect; and a method of treatment of vocal fold scarring and repair of skin and soft tissue defects.

[0004] Also known in the art are dosage units consisting of autologous fibroblasts grown for an individual who is also the donor. Further, there are known methods of growing fibroblasts for use in autologous applications.

[0005] Deriving a commercial, non-autologous product from a mixture of two or more tissue cultures of fibroblast or extracts from cultures or media cultures isolated from separate individuals, either homogeneous or heterogeneous

SUMMARY OF THE DISCLOSURE

[0006] The present disclosure provides a non-autologous product.

[0007] The present disclosure further provides such a non-autologous product that is a homogeneous and heterogeneous mixture of two or more fibroblasts cultures, extracts derived therefrom, and/or diffusible elements recovered from the culture media from the same sex.

[0008] The present disclosure also provides that each mixture of homogeneous and/or heterogeneous fibroblasts cultures or extracts therefrom from the same sex can have "weighted" factors based on the characteristics desired to be obtained by the mixture.

[0009] The present disclosure still further provides that the fibroblast cultures or extracts therefrom or the diffusible elements that form the cell culture can be influenced to produce variations in the product or resultant product.

[00010] The present disclosure, in addition, provides that for each product there can be at least three factors with one or more factors having greater weight.

[00011] The present disclosure yet provides that the factors include, but are not limited to, age, DNA testing, ethnic homogeneity, health, physical beauty (adherence to classic beauty as described by the golden ratio, sometimes referred to as a Fibonacci series) to produce or create variations in the product or different resultant products. These different resultant products can be directed to enhance, modulate or treat one or more desired characteristics of the user of the composition of the present disclosure.

[00012] The present disclosure further provides methods of using the heterogeneous and/or homogeneous mixtures of fibroblasts or extracts therefrom or the diffusible elements that form the cell culture, from the same sex, to provide a non-autologous product.

[00013] The present disclosure additionally provides methods of making, i.e. culturing, of the mixture including aspects of enhancing the beneficial effects or modulating the effects of the mixture.

BRIEF DESCRIPTION OF THE DRAWINGS

[00014] FIGS. 1 to 4 are graphs of test results that demonstrate differences in the overall expression profiles.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[00015] As stated above, the present disclosure provides a mixture of two or more tissue cultures of fibroblasts, coculture of cells, extracts from cells or cultures, diffusible elements that form the cell culture, or culture media isolated from separate individuals, whether homogeneous and heterogeneous from the same sex. The use of fibroblast cultures, coculture of cells, extracts from cells or cultures, diffusible elements that form the cell culture, or culture media, either alone or with environmental conditions, are used to grow cells and induce the cells to produce their array of elements produced by or extracted from the cells. These cells, cultures, coculture of cells, diffusible elements that form the cell culture and culture media and/or factors are blended together in a product that imparts desired characteristics to the skin of a recipient. Significantly, since the recipient is not the source of the mixture or any individual fibroblast, the relationship between the recipient and the fibroblasts is referred to as "non-autologous". Since the products are intended for a specific sex, namely women or men, the blend of cells, cocultures, cultures, diffusible elements that form the cell culture, and culture media and/or elements in each product are derived from the desired sex.

[00016] These elements produced by or extractable from the cells, cultures, culture media and/or elements as stated above, are blended together and included in the product. The elements include, but are not limited to, growth factors including epidermal growth factors, proteins, peptides, cytokines and all other biomolecules present in the cell or media culture.

[00017] According to the present disclosure, the product will preferably be a topical composition. The preferred the topical composition is a cream, serum or lotion. The composition can include delivery vehicles, such as liposomes and micelles. The composition can also include transport molecules, such as a protein or a macromolecule that promotes or provides molecular sledding. The use of such transport molecules enables delivery of the elements to the epidermis or dermis of a recipient. However, the composition can be parental (e.g. injectable, intravenous, or the like), delivered by device (e.g. laser, micronneedle, inhaler, or the like), or an oral periodontal including a mouthwash.

[00018] The tissue culture fibroblasts or fibroblast cells or cultures or extracts from cultures, diffusible elements that form the cell culture, or media cultures can also be influenced to produce variations in the array of elements produced by or extractable from the cells or media culture, the amount and type of elements, due to the exposure to different chemical, culture or environmental elements of the growth medium of the cultures. For example, oxygen level (hypoxia, hyperoxia, and normative oxygen levels), AOX, pH, temperature, and exposure of the cells to different levels of UV light and different mixtures of UVA, UVB, UVC, IR, and visible light, can effect or influence the fibroblast cultures or extracts therefrom. Further, environmental conditions can affect the culture fibroblasts, or fibroblast cultures, or extracts from cultures, or media cultures, or elements. Such environmental conditions include, but are not limited to, PO₂, CO, (hyper or hypo oxygen conditions) exposure to different bands of UV or other forms of energy, temperature and the like.

[00019] As used herein, the term “homogeneous” means the use of fibroblast cultures obtained from donors who constitute a group whose bloodlines are 80% or greater of a single race or ethnicity, preferably 90% or greater, more preferably 95 % or greater, and most preferably essentially

100%. Thus, a fibroblast culture obtained from a homogeneous set of donors (of the same-sex), such as a group of: Japanese women, or West African women, or Indian women. Because of centuries-old racial intermixes, the term "homogeneous" generally does not apply to groups selected from cultures such as, for example, those in America or the Caribbean Islands.

[00020] The term "heterogeneous", as used herein, means the use of non-ethnic homogeneity fibroblasts, such as fibroblasts obtained from same-sex, but a combination of different groups or sources, such as, for example, a group of: West African women and Japanese women, or West African women and Indian women, or Japanese women and Western European women.

[00021] The mixtures of homogeneous and/or heterogeneous tissue cultures of fibroblasts of the present disclosure can be "tailored" to include more of one ethnic group than another. Further, the "tailoring" can include consideration of factors that are "weighted" based on the characteristics desired to be obtained by the mixture. The factors include, but are not limited to, age, DNA testing, ethnic homogeneity, health, and physical beauty (adherence to classic beauty as described by the golden ratio, sometimes referred to as a Fibonacci series), to produce variations in the product or different resultant products. These different resultant products can be directed to enhance one or more desired characteristics of the user of the composition of the present disclosure.

[00022] For example, a mixture of tissue cultures of fibroblasts can comprise 50% fibroblasts from a West African woman, 30% fibroblasts from a Japanese woman, and 20% fibroblasts from an Indian woman. Each percentage can be obtained from either a single woman or a group of women constituting a homogenous mixture, as the term homogenous has been defined above, such as a plurality of women from the West African nation of Mali. The selection of the fibroblasts and the weighing of factors for the mixture are predicated on the particular pigment or other characteristic desired

to be improved or imparted to the skin of a recipient. Thus, it should be understood that according to one embodiment of the present disclosure, the composition provides a selection of ethnic group or groups of donors and possibly a "weighted" mixture to achieve a resultant product that delivers at least one property, preferably to the skin. The one property can be, for example, enhanced skin firmness or smoothness, or more fullness of the skin. Moreover, that one property can be improved on virtually any person (of any ethnic background) that uses the composition of this embodiment of the present disclosure.

[00023] The particular characteristics desired to be imparted to the skin of a recipient can include, but are not limited to, skin tone, skin elasticity, skin smoothness, reduced scarring, reduced wrinkles, response to inflammatory stimulus, ability to retain moisture, propensity to produce new vasculature and deliver nutrients and skin thickness or density, improve response to injury or free-radical damage, or combination of skin characteristics that will be apparent to those of skill in the art based upon the present disclosure. Because the mixtures of homogeneous and/or heterogeneous fibroblast cultures can be "tailored" to provide a specific desirable skin characteristic or combination of skin characteristics, the present disclosure provides limitless possibilities for imparting characteristics to the skin of a recipient. Thus, "tailoring" can include a larger percentage of fibroblast cultures from one homogeneous or heterogeneous woman or group of women since that woman or group are known or believed to provide the desired characteristic.

[00024] It is believed that skin wrinkling is a problem of lighter skin types. Also, mottled hyperpigmentation and uneven skin tone is associated with the darker skin types. Further, Asian descents have mechanisms to protect against photoaging. Thus, the above can be considered in deciding the tailoring including weighing based on the skin characteristic or combination of skin characteristics desired in the product. As shown by the test data below,

increased HAS1 in CoCulture relative to one group (or monoculture) shows both improved antiwrinkling and photodamage prevention or minimalization. This underscores the ability to produce compositions according to the present disclosure in which tailoring or customization of a composition is achievable. The test data in the present disclosure proves that any combination of cells or cocultures, and supports the belief that any combination of extracts from cells or cultures, diffusible elements that form the cell culture, culture media or external factors, can add Col1a1 stimulation and/or MMP1 suppression to HAS1 (hyaluronic acid) production in a composition to produce an anti-aging product.

[00025] In a preferred embodiment, it is believed that the “weighed” mixture, has a hierarchy among the factors. Preferably, for an ethnic homogeneity, (1) health, (2) age, and (3) beauty factors in this order of priority are considered.

[00026] Concerning the health factor, it is important to consider eliminating donors having a genetic disease. Also, premature aging due to environmental conditions, such as free radical generating, namely sun and higher neoplasms, as well as premature aging due to smoking, should be eliminated from the donor “pool”.

[00027] For the age factor, the donor “pool”, especially of women, the age of the donors from which the fibroblasts are derived is preferably of a young age since their skin and fibroblasts are at an optimal state of life. Such an age range can vary based on ethnicity. It is believed that the preferred age range is from 18 to 35, more preferably 18 to 30 years of age. However, it is envisioned that the age range can have a lower limited possibly to the age of a mature individual, which in the U.S. is a teenager, namely about 12 years of age.

[00028] For the beauty factor, the adherence to classic beauty as described by the golden ratio, sometimes referred to as a Fibonacci series, has a number of desirable features. These desirable features include, but are not limited to, the geometric relationship between the angles and spacings of key features or elements of the face including, but not limited to, the mouth, eyes, and arch of brow. The selection of such features will be included in the “tailoring” of the eventual product. Thus, products can be made to be customized to the intended recipients.

[00029] As discussed above, it is also believed that the present disclosure can be used for other purposes. For example, the present compositions can be used to heal a wound or to mitigate scarring. Thus, it is envisioned that the intra epidermal, dermal and SQ, not just the epidermis layer, can be affected by the compositions and methods of the present disclosure.

[00030] The present disclosure also provides methods of making, i.e. culturing, fibroblast mixtures and, moreover, optimizing such culturing. As well known, the fibroblast cultures can take a significant amount of time to grow to sufficient numbers and generally require multiple passages of the fibroblasts in culture media to obtain satisfactory yields. Also, the method of making the fibroblasts can be modified by processes, such as, external and/or environmental elicitation. Further, the fibroblasts can be genetically modified. Still further, the fibroblasts can be converted from the skin or non-skin sources, such as, for example, umbilical cord mesenchymal stem cells. According to the present disclosure, the fibroblast cultures can be obtained from an animal, such as a mammal, in accordance with methods known in the art. Preferably, the fibroblast cultures are obtained by isolating fibroblasts from the same type of tissue that is the object of the methods of use of the present disclosure. Methods of culturing fibroblasts including culture media and culturing techniques, such as passaging and selection are also known in the art. Usual cultured media include bovine serum albumin or fetal calf serum that is FBS

free. However, the fibroblasts can be cultured in serum mixture of the donors. Preferably, collagen-producing fibroblasts are selected.

[00031] The present disclosure envisions that the potencies of the fibroblast culture mixture obtained according to the methods of making can be beneficially modified for improved efficacy or optimization. For example, improved potency or altering elements can be achieved by modifying the oxygen level under which the culturing and fibroblast growth is performed. It is possible to modulate the potency of the homogeneous and/or heterogeneous fibroblast culture mixture by adjusting the oxygen level under which the fibroblasts are cultured.

[00032] In combination with the ability to prepare the "tailored" "weighted" mixtures of homogeneous and/or heterogeneous fibroblast cultures, the ability to modulate the potency of the resulting fibroblast cultured mixture by adjusting the oxygen level under which the mixtures of fibroblast cultures are grown provides a wide range of options, including therapeutic options, according to the present disclosure.

[00033] As discussed herein, in a preferred embodiment directed to women. However, the present disclosure can also be used for men. Thus, there can be the same principals and teachings applied, as discussed above, for men.

[00034] Human skin fibroblasts from female humans of African American [African American group] and Asian [Asian/Korean group] background of a low passage were seeded into 6 well dishes. This was done for both groups in single culture and in a 50:50 combination ratio of African American to Asian/Korean. The cells were cultured until approximately twenty-four (24) hours after the cells reached confluency (tightly packed monolayer). At 24 hours post confluency, cells were then lysed and RNA extracted using a phenol:chloroform extraction method (Trizol Reagent). The RNA was then

quantified and concentration of RNA evaluated. This RNA was converted to cDNA using the SABiosciences RT² Easy First Strand kit. The cDNA was mixed with SYBR green detection agent and added to the wells of other SABiosciences RT² ECM and Adhesion molecule array, per kit instructions. The array was loaded into a Bio-Rad iCycler for array performance and data capture. Analysis was performed using web based software designed specifically for the array.

[00035] The results of one experimental replicates per parameter were evaluated from the web based software for fold regulation changes between control and exposed cells, and statistical significance/p-value determination. The genes on the array(s) were then examined for dysregulation (with or without statistical significance) to determine what areas of the array have the most dysregulation and are most likely to be the processes effected. Since only one array per sample was run, p-values could not be generated and values listed below were only be analyzed for biological significance (greater than 2 fold increase or decreased gene expression value relative to control). All gene values were normalized to HPRT1,B2M, GAPDH and RPLP0 in the Control Gene List. The Asian/Korean group of cells were set as the Control sample, so the following comparisons are gene dysregulation relative to Asian/Korean expression levels as set forth in the Gene Expression Value Summary Table below.

Symbol	Description	African American Fold Change	1:1 Ratio Asian:African American Fold Change
ADAMTS1	ADAM metalloproteinase with thrombospondin type 1 motif, 1	-1.3	-2.7
ADAMTS13	ADAM metalloproteinase with thrombospondin type 1 motif, 13	-1.3	31.5
ADAMTS8	ADAM metalloproteinase with thrombospondin type 1 motif, 8	-1.0	41.5
CD44	CD44 molecule (Indian blood group)	-1.4	-1.7

CDH1	Cadherin 1, type 1, E-cadherin (epithelial)	-1.0	41.5
CLEC3B	C-type lectin domain family 3, member B	-2.2	18.1
CNTN1	Contactin 1	-1.0	41.5
COL11A1	Collagen, type XI, alpha 1	-52.9	-1.3
COL12A1	Collagen, type XII, alpha 1	-2.9	-1.8
COL14A1	Collagen, type XIV, alpha 1	2.3	7.3
COL15A1	Collagen, type XV, alpha 1	-52.9	-1.3
COL16A1	Collagen, type XVI, alpha 1	-1.8	2.6
COL1A1	Collagen, type I, alpha 1	-1.4	1.5
COL4A2	Collagen, type IV, alpha 2	-2.0	1.1
COL5A1	Collagen, type V, alpha 1	-1.2	1.2
COL6A1	Collagen, type VI, alpha 1	-1.0	2.3
COL6A2	Collagen, type VI, alpha 2	1.1	-1.1
COL7A1	Collagen, type VII, alpha 1	-2.2	3.9
COL8A1	Collagen, type VIII, alpha 1	-1.9	2.4
CTGF	Connective tissue growth factor	-1.9	-3.3
CTNNA1	Catenin (cadherin-associated protein), alpha 1, 102kDa	-2.0	-2.0
CTNNB1	Catenin (cadherin-associated protein), beta 1, 88kDa	-1.0	41.5
CTNND1	Catenin (cadherin-associated protein), delta 1	-1.3	5.6
CTNND2	Catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein)	-1.0	41.5
ECM1	Extracellular matrix protein 1	-1.3	-1.3
FN1	Fibronectin 1	-1.4	-1.5
HAS1	Hyaluronan synthase 1	-1.0	41.5
ICAM1	Intercellular adhesion molecule 1	2.3	11.9
ITGA1	Integrin, alpha 1	-5.0	-3.3
ITGA2	Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)	-3.1	-2.7
ITGA3	Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)	-2.3	-1.2
ITGA4	Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)	-2.0	-4.7
ITGA5	Integrin, alpha 5 (fibronectin receptor, alpha polypeptide)	-1.8	1.2
ITGA6	Integrin, alpha 6	-2.5	-1.4
ITGA7	Integrin, alpha 7	-2.2	10.4
ITGA8	Integrin, alpha 8	-2.0	3.2
ITGAL	Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated	2.0	41.5

	antigen 1; alpha polypeptide)		
ITGAM	Integrin, alpha M (complement component 3 receptor 3 subunit)	1.5	41.5
ITGAV	Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)	-1.2	-2.0
ITGB1	Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)	-1.8	-11.5
ITGB2	Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)	-1.3	31.5
ITGB3	Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)	1.1	6.8
ITGB4	Integrin, beta 4	-1.0	41.5
ITGB5	Integrin, beta 5	-3.1	-2.3
KAL1	Kallmann syndrome 1 sequence	-1.0	41.5
LAMA1	Laminin, alpha 1	-1.0	41.5
LAMA2	Laminin, alpha 2	-3.3	-1.7
LAMA3	Laminin, alpha 3	-7.6	5.6
LAMB1	Laminin, beta 1	-1.3	-1.5
LAMB3	Laminin, beta 3	27.4	54.8
LAMC1	Laminin, gamma 1 (formerly LAMB2)	-1.5	-2.0
MMP1	Matrix metallopeptidase 1 (interstitial collagenase)	-16.3	-13.2
MMP10	Matrix metallopeptidase 10 (stromelysin 2)	-1.0	41.5
MMP11	Matrix metallopeptidase 11 (stromelysin 3)	-1.3	19.4
MMP12	Matrix metallopeptidase 12 (macrophage elastase)	-1.3	31.5
MMP13	Matrix metallopeptidase 13 (collagenase 3)	-1.0	41.5
MMP14	Matrix metallopeptidase 14 (membrane-inserted)	-1.9	-1.9
MMP15	Matrix metallopeptidase 15 (membrane-inserted)	8.4	41.5
MMP16	Matrix metallopeptidase 16 (membrane-inserted)	-4.1	-2.7
MMP2	Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)	-2.5	-1.4
MMP3	Matrix metallopeptidase 3 (stromelysin 1, progelatinase)	-10.7	-5.4
MMP7	Matrix metallopeptidase 7 (matrilysin, uterine)	-1.0	41.5
MMP8	Matrix metallopeptidase 8 (neutrophil	-1.0	41.5

	collagenase)		
MMP9	Matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)	-1.0	41.5
NCAM1	Neural cell adhesion molecule 1	-1.9	9.0
PECAM1	Platelet/endothelial cell adhesion molecule	2.8	18.1
SELE	Selectin E	-1.0	41.5
SELL	Selectin L	-1.0	41.5
SELP	Selectin P (granule membrane protein 140kDa, antigen CD62)	-1.0	41.5
SGCE	Sarcoglycan, epsilon	1.1	1.8
SPARC	Secreted protein, acidic, cysteine-rich (osteonectin)	-3.5	-1.7
SPG7	Spastic paraplegia 7 (pure and complicated autosomal recessive)	-1.5	1.7
SPP1	Secreted phosphoprotein 1	-5.8	3.9
TGFBI	Transforming growth factor, beta-induced, 68kDa	-2.7	-3.8
THBS1	Thrombospondin 1	-1.7	-17.4
THBS2	Thrombospondin 2	-2.3	-1.2
THBS3	Thrombospondin 3	-1.0	41.5
TIMP1	TIMP metalloproteinase inhibitor 1	-1.8	-1.3
TIMP2	TIMP metalloproteinase inhibitor 2	-1.5	-1.3
TIMP3	TIMP metalloproteinase inhibitor 3	-6.2	-8.7
TNC	Tenascin C	-1.3	1.1
VCAM1	Vascular cell adhesion molecule 1	-1.0	41.5
VCAN	Versican	-3.3	-10.0
VTN	Vitronectin	-1.0	41.5

[00036] What these tests showed is the ability to mix fibroblasts or cells of different groups or ethnic groups or CoCulturing can be obtained. This can be done at the cell stage, and not just at the cultured media stage. Further, by examining the overall expression profiles (expression values of every gene tested on the array plotted as a line graph), distinct differences in the profiles of African American cells and those African American cells with the Asian/Korean cells, hereinafter called "CoCulture" at a 50:50 ratio were observed. With the Asian/Korean group as control and thus serving as the baseline (or 0 line on the graph), the graphs shown in Figs. 1-4 clearly demonstrate differences in the overall expression profiles. CoCulture shows a

greater magnitude of change than just comparing African American group cells to Asian group cells. In a select few instances, the CoCulture demonstrates a directionally opposed dysregulation from the African American cells (where CoCulture is upregulated, the African American cells are downregulated).

Functional Gene Group	African American		CoCulture of African American and Asian/Korean	
	% of Group Altered	% of Altered Upregulated	% of Group Altered	% of Altered Upregulated
Transmembrane Molecules	39%	25%	77%	71%
Cell-Cell Adhesion	22%	50%	44%	100%
Cell-Matrix Adhesion	43%	0%	76%	63%
Other Adhesion Molecules	23%	17%	65%	76%
Basement Membrane Constituents	44%	25%	44%	75%
Collagens & ECM Structural Constituents	43%	17%	43%	100%
ECM Proteases	28%	20%	78%	71%
ECM Protease Inhibitors	17%	0%	50%	33%
Other ECM Molecules	45%	0%	73%	63%

[00037] The CoCulture exhibits a more stimulatory effect (increased protein production) on the genes of the functional groups, while the African American monoculture demonstrates a more inhibitory (decreased protein production) effect. CoCulture also demonstrates more activity in the genes involved with the majority of the functional groups listed. Only Basement Membrane Constituents and Collagens & ECM Structural Constituent

pathways demonstrate the same level of dysregulation (although they still demonstrate a stronger stimulatory effect in the CoCultured cells).

[00038] The results of the testing illustrate the following. The enablement for the mixture of fibroblasts cells of two or more donors or different ethnic groups. Further, the test supports distinct differences in the profiles of African American cells than those in CoCulture (50:50 of African American and Asian/Korean). Namely, CoCulture provides: (1) larger stimulatory effect on protein production, (2) a greater degree in pathways related to transmembrane molecules, adhesion molecules (cell-cell; cell-matrix and others), ECM Proteases and inhibitors, (3) different gene expression, (4) significant increase in HAS1 (Hyaluronan Synthase), (5) an increase in COL7A1 (loss of COL7A1 can contribute to wrinkle formation according to scientific literature); and (6) a greater number of MMPs involved.

[00039] Accordingly, the tailored and/or customized blending envisioned by the present disclosure even at the cell level clearly has unexpectedly be found can be done.

[00040] It should be understood that the present disclosure will be a topical composition. Preferably, the topical composition is a cream applied to the recipient. The cream or cream product will have a vehicle. The vehicle is to allow for the application to the recipient's skin and not obfuscate the effect of the fibroblast mixture. It is believed that a major percentage of the vehicle will be water. It is also envisioned that the amount of the mixture of fibroblast cultures in the total topical composition or cream will be less than 5 percent (%) and preferably less than 1 percent. It is envisioned that less than 1 percent will produce optimum results in a topical composition.

We claim:

1. A non-autologous topical product comprising a mixture of two or more tissue cultures of fibroblast or extracts from cultures or media cultures isolated from separate individuals, either homogeneous or heterogeneous based on one or more desired product characteristics to be imparted on the skin of a recipient.
2. A non-autologous topical product that uses of fibroblast cultures, extracts from cells or culture media, either alone or with environmental conditions, to grow the cells and induce them to produce their array of elements produced by or extracted from the cells, and that these cells or factors are blended together in a product that imparts one or more desired characteristics to the skin of a recipient.
3. The product of claim 2, wherein the mixture can be tailored to include two or more ethnic groups
4. The product of claim 3, wherein the two or more ethnic groups have a greater percentage of donors from one group than the other group or groups.
5. The product of claim 3, wherein the tailored mixture includes consideration of factors that are weighted based on the characteristics desired to be obtained by the mixture.
6. The product of claim 5, wherein the weighed factors includes one factor.
7. The product of claim 5, wherein the one factor is a plurality of factors.
8. The product of claim 6, wherein the plurality of factors include age, ethnic homogeneity, health and physical beauty of each donor.

9. The product of claim 8, wherein the age factor includes donors only between 12 and 35 years of age.
10. The product of claim 8, wherein the age factor includes donors only between 18 and 30 years of age.
11. The product of claim 8, wherein the health factor includes eliminating donors having a genetic disease and premature aging due to environmental conditions.
12. The product of claim 11, wherein the environmental conditions include free radical generation.
13. The product of claim 12, wherein the free radical generation includes sun, smoking and higher neoplasms.
14. The product of claim 8, wherein the beauty factor includes adherence to the golden ratio.
15. The product of claim 2, wherein the topical product is selected from a group consisting of a cream, serum, and lotion.
16. The product of claim 2, wherein the desired characteristics are selected from the group consisting of: skin tone, skin elasticity, skin smoothness, reduced scarring, reduced wrinkles, response to inflammatory stimulus, ability to retain moisture, propensity to produce new vasculature, deliver nutrients, skin thickness or density, and any combinations thereof.
17. The product of claim 16, wherein the desired characteristics determine the tailoring and weighing of the product.

18. The product of claim 1, wherein the product is used to optimizing the potency or potential of a mixture to impart the desired characteristics to the skin of the recipient.

19. A method of making a non-autologous topical product from two or more tissue cultures of fibroblast or extracts from cultures or media cultures isolated from separate individuals, either homogeneous or heterogeneous based on one or more desired product characteristics to be imparted on the skin of a recipient.

20. The method of claim 19, wherein the product can be tailored to include two or more ethnic groups with one ethnic group having a greater percentage of donors from than the other group or groups.

FIG. 1




FIG. 2




FIG. 3





FIG. 4



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 14/65627

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - C12N 5/0775; A61Q 19/08; A61K 8/98 (2014.01)
CPC - A61Q 19/00; A61Q 19/08; A61K 8/985
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC(8): C12N 5/0775; A61Q 19/08; A61K 8/98 (2014.01)
CPC: A61Q 19/00; A61Q 19/08; A61K 8/985

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC: 424/572; 435/325 (Keyword limited, terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 PatBase, Google Patents, Google Scholar (NPL); Keywords: fibroblast; mixture/combination/blend, non-autologous, topical, skincare, tissue culture, different/separate individual/donor

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	WO 2011/015862 A1 (Jahoda et al.) 10 February 2011 (10.02.2011) pg 1, para 1; pg 4, para 12-13; pg9, para 5; pg 11, para 3; pg 12, para 2-5; pg 13, para 2	2, 15 ----- 1, 3-14, 16-20
Y	US 2001/0048917 A1 (Hoeffler et al.) 06 December 2001 (06.12.2001) para [0036], [0041], [0045], [0047], [0052], [0068]	1, 3-14, 18-20
Y	US 2007/0128174 A1 (Kleinsek et al.) 07 June 2007 (07.06.2007) para [0003], [0006], [0007], [0010], [0058], [0061], [0163], [0166]-[0187], [0548], [0587], [0615], [0617], [0620]-[0629], claim 1	3-14, 16-17, 20

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
07 January 2015 (07.01.2015)

Date of mailing of the international search report
29 JAN 2015

Name and mailing address of the ISA/US
 Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450
 Facsimile No. 571-273-3201

Authorized officer:
 Lee W. Young
 PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774